KinetaKA
KA
$0.5691
0.96%
Market Cap: $6.98M
About: Kineta Inc is a clinical-stage biotechnology company with a mission to develop next generation immunotherapies that transform patients' lives. The company's asset is KVA12.1, a VISTA blocking immunotherapy.
Employees: 11
0
Funds holding %
of 6,710 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
11% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 9
4% more funds holding
Funds holding: 25 [Q1] → 26 (+1) [Q2]
7.92% less ownership
Funds ownership: 13.92% [Q1] → 6.0% (-7.92%) [Q2]
17% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 6
52% less capital invested
Capital invested by funds: $801K [Q1] → $388K (-$413K) [Q2]
Research analyst outlook
We haven’t received any recent analyst ratings for KA.